In 2015, 28,486 unintentional deaths related to falls occurred among people aged 65 and older, which represented a rate of nearly 60 unintentional fall deaths per 100,000 men and women aged 65 and older.

Those who fell were significantly more likely to be female, Caucasian, older, and lower income. Fallers also had significantly lower self-rated health and reported more chronic conditions.

of adults aged 65 and older fall each year.

30% 33%

of those who fall seek medical care.

is the estimated medical costs associated with fatal falls in 2015.

$754 MILLION 25%

of older adults reported a non-fatal fall in the past year; 52% fell once, 21% fell twice, and 24% fell three or more times.

$12.9 BILLION 6%

of hospital expenditures (4.4%) were attributable to older adult falls.

of Medicare expenditures and 8% of Medicaid expenditures were attributable to falls.


in total healthcare spending was attributable to falls in 2015, including expenditures of $28.9 billion for Medicare, $8.7 billion for Medicaid, and $12 billion for other payment sources.

Source: Journal of the American Geriatrics Society, March 7, 2018. 6

FDA warns duodenoscope manufacturers postmarket surveillance study compliance The U.S. Food and Drug Administration issued warning letters to all three duodeno- scope manufacturers for failing to comply with requirements of federal law under which they were ordered to conduct post- market surveillance studies to assess the effectiveness of reprocessing the devices. As part of an ongoing effort to prevent patient infections associated with the trans- mission of bacteria from contaminated duodenoscopes, the FDA in 2015 ordered U.S. duodenoscope manufacturers Olympus, Fuji lm and Pentax to conduct a postmarket surveillance study to determine whether healthcare facilities were able to properly clean and disinfect the devices.

Specifcally, as part of their approved study plans, all three manufacturers are required to conduct a study to sample and culture repro- cessed duodenoscopes that are in clinical use to learn more about issues that contribute to contamination, as well as a human factors study to assess how well trained hospital staff are following the reprocessing instructions. “The FDA has taken important steps to im- prove the reprocessing of duodeno- scopes, and we’ve seen a reduction in reports of patient infections, but we need the required postmarket studies to determine whether these measures are being properly imple- mented in real world clinical settings and whether we need to take additional action to further improve the safety of these devices,” said Jeff Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. The FDA has worked with all three duo- denoscope manufacturers that market duo- denoscopes in the U.S. to review validated processing instructions and to take corrective actions to remove and replace models from the market with faulty designs that made them dif cult to clean and reprocess. On February 26, 2018, the FDA, Centers for Disease Control and Prevention (CDC), and the American Society for Microbiology (ASM), together with other endoscope cul- turing experts, released voluntary standard- ized protocols for duodenoscope surveillance sampling and culturing.

For healthcare facilities that choose to

implement duodenoscope surveillance sampling and culturing, these protocols can be used to help monitor the quality of a facility’s endoscope reprocessing procedures. Adequate monitoring may reduce the risk of infection. FDA expected Olympus, Fujiflm and Pen- tax to submit a plan in late March that out- lines how study milestones will be achieved. The agency expects 50 percent of testing to be completed by May 31, 2018 and 100 percent


by June 30, 2018. If the companies fail to adequately respond to the warning letter, the FDA may take additional action such as seizure, injunction and civil money penalties.

HIMSS Analytics announces collaboration to advance supply chain capacity in global health systems HIMSS Analytics announced a collaboration with Dr. Anne Snowdon, Professor of Strate- gy and Entrepreneurship, Chair of the World Health Innovation Network (WIN) and CEO of the Supply Chain Advancement Network (SCAN Health) located at the University of Windsor, Ontario, Canada.

Through this unique initiative HIMSS Analytics will accelerate the development and launch of evidence-based tools to sup- port supply chain transformation in global health systems.

“As technology solutions become in-creas-

ingly integrated the ability to leverage supply chain tools, processes and information across global health systems becomes essential to improve performance and population health outcomes,” said Hal Wolf, III, FHIMSS, Presi- dent and CEO, HIMSS.

Dr. Snowdon is leading an extensive pro- gram of research at WIN, creating empirical evidence of the impact and value of supply chain maturity in health systems. Through her research she works with industry and health systems to design predictive arti cial intelligence tools that support clinicians and assess the matu- rity of supply chain infra- structure across healthcare organizations. Dr. Snowdon has developed a ground- breaking supply chain maturity tool Health - Supply Information Maturity Management (H-SIMM) to support health organizations to assess their progress to- wards a strategic supply chain infrastructure that contributes to quality, safety and sustainability. HIMSS Analytics will collaborate with Dr. Snowdon working with her research team to validate the innovative tool, dis- seminate the findings, and launch the H-SIMM. “Partnering with HIMSS gives us tre- mendous reach into healthcare systems to accelerate the adoption of leading supply chain best practices and to amplify knowl- edge exchange to improve performance, safety and health outcomes,” explained Dr. Snowdon.

Dr. Snowden’s presentation included experiences of global supply system lead- ers: AHS, Canada — Jitendra Prasad; NHS England — Dr. Charles Alessi; and Mercy, St. Louis, Supply Chain Director, Curtis Dudley. The presentation-framed research on how system level measurements of pa- tient out- comes to product use and care procedures typically does not exist at most facilities today

Page 8

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62